Phenotypic heterogeneity of myelodysplastic cells and influence of epigenetic therapies (WP1)
Rationale and objectives
The project aims to:
1) determine the cellular mode of action of IDHis in myelodysplastic syndromes (MDS) in monotherapy or in combination with Azacitidine;
2) identify at the single-cell level the gene expression signatures associated with resistance to IDHis as monotherapy or in combination with Azacitidine;
3) identify in vitro and then validate in vivo therapeutic combinations reverting the expression of resistance signatures to IDHis.
GenomeScan B.V. (The Netherlands, 2 months), University of Bergen (Norway, 2 months), Institute for Tumor Biology and Experimental Therapy Georg-Speyer-Haus (Germany).
PhD program in Hematology, University of Paris (France), Doctoral School in Hematology-Oncogenesis-Biotherapies.